Alzheimer’s: Delhi pharmaceutical company obtains drug candidate from Bengaluru scientists | India News

BENGALURU: More than a year after scientists at the Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR) developed a drug molecule to prevent the mechanism that makes neurons (brain cells) dysfunctional in Alzheimer’s disease (AD), its intellectual property (IP) was transferred to a Delhi-based pharmaceutical company.
Hamsa Biopharma, which will take the drug – dubbed TGR63 – through trials through its US parent company IGC Pharma, hopes it can eventually be made available on the market.
TOI was the first to report on Professor T Govindaraju and the team developing ‘TGR63’ in its February 26, 2021 edition. Although treatments available on the market provide temporary relief, there are no approved drugs. which acts directly on the pathological mechanisms of Alzheimer’s disease, which the scientists of JNCASR and Hamsa believe that “TGR63” has the potential to do.
Ram Mukunda, CEO of IGC Pharma, told TOI: “We got in touch with Professor Govindaraju after hearing about the molecule, which we believe can be a game-changer, in March-April 2021. We analyzed the molecule, the study and the results and our experts found there was potential.
Drug candidate
Govindaraju, reiterating how ‘TGR63’ has the potential to stop or cure the leading cause of dementia, explained that in the Alzheimer’s disease brain, abnormal levels of naturally occurring proteins clump together to form plaques that build up between neurons and disrupt cellular function.
“…This is caused by the production and deposition of a protein called amyloid peptide (Aß) which accumulates in the central nervous system. The multifactorial nature of AD has prevented researchers from developing an effective treatment until now, but we now have a candidate that could reduce Aß toxicity,” he added.
The JNCASR has already established – through laboratory and animal (mouse) tests – that “TGR63” can rescue neuronal cells from amyloid toxicity.
“The brains of AD mice treated with “TGR63” showed a significant reduction in amyloid deposits, validating its therapeutic efficacy. The mice also showed reductions in learning deficit, memory impairment, and cognitive decline, as revealed by separate behavioral tests. These key attributes validate the potential of ‘TGR63’ as a promising drug candidate for AD,” Govindaraju reiterated.
After that
Mukunda said the company will begin testing the molecule for toxicity and absorption in primates. “Once we can document all the data and show it is safe when used in primates, which is a process that is expected to take about a year, we can proceed to phase I trials in humans. ‘male. Here we would test the safety and tolerance of the molecule in humans,” he said.
He said the company would fast-track testing and in about 12 months or so it would be ready to seek regulatory approval for phase I human trials.
“Once approved, this process should continue for another year, where we would essentially test security among different groups. While the first tests will take place in India, we may need to transfer them to the United States, Canada or South America for testing in primates and humans,” Mukunda said.
After the safety trials, the company would seek authorization to embark on phase II human trials – efficacy testing – whose protocols would be prepared in consultation with the team of Professor Govindaraju and other experts from the JNCASR .
“Phase II trials could take 24 to 30 months, after which we would be ready with a product that could help hundreds of thousands of people around the world. We are confident that the molecule works and the work done at JNCASR is truly groundbreaking,” Mukunda said.

Comments are closed.